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Blood pressure reduction is an important and effective strategy in stroke prevention in hypertensives. 
Recently, we found that baroreflex restoration was also crucial in stroke prevention. The present 
work was designed to test the hypothesis that a combination of blood pressure reduction and 
baroreflex restoration may be a new strategy for stroke prevention. In Experiment 1, the effects 
of ketanserin (0.3, 1, 3, 10 mg/kg), amlodipine (0.3, 1, 2, 3 mg/kg) and their combination (1 + 0.3, 
1 + 1, 1 + 2, 1 + 3 mg/kg) on blood pressure and baroreflex sensitivity (BRS) of stroke-prone 
spontaneously hypertensive rats (SHR-SP) were determined under conscious state. It was found 
that both amlodipine and ketanserin decreased blood pressure dose-dependently. Ketanserin 
enfanced BRS from a very small dose but amlodipine enfanced BRS only at largest dose used. 
At the dose of 1 + 2 mg/kg (ketanserin + amlodipine), the combination possessed the largest 
synergism on blood pressure reduction. In Experiments 2 and 3, SHR-SP and two-kidney, two-clip 
(2K2C) renovascular hypertensive rats received life-long treatments with ketanserin (1 mg/kg) 
and amlodipine (2 mg/kg) or their combination (0.5 + 1, 1 + 2, 2 + 4 mg/kg). The survival time was 
recorded and the brain lesion was examined. It was found that all kinds of treatments prolonged 
the survival time of SHR-SP and 2K2C rats.  The combination possessed a significantly better effect 
on stroke prevention than mono-therapies. In conclusion, combination of blood pressure reduction 
and baroreflex restoration may be a new strategy for the prevention of stroke in hypertension.
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Materials and Methods
aniMals
Sprague-Dawley (SD) rats were provided by Sino-British SIPPR/
BK Lab Animal Ltd (Shanghai, China) and SHR-SP by the Animal 
Center of our university. They were housed with controlled tempera-
ture (23–25°C) and lighting (8:00–20:00 light, 20:00–8:00 dark) and 
with free access to standard food and drinking water. All the animals 
used in this work received humane care in compliance with institu-
tional guidelines for health and care of experimental animals.
Blood pressure MeasureMent
Systolic blood pressure (SBP), diastolic blood pressure (DBP) and 
heart period were continuously recorded using previously described 
technique with some modifications (Su et al., 1986). Briefly, rats 
were anesthetized with a combination of ketamine and diazepam. 
A polyethylene catheter was inserted into the lower abdominal 
aorta via the left femoral artery for blood pressure measurement 
and another catheter was inserted into left femoral vein for phe-
nylephrine administration. A third catheter was placed into the 
stomach via a mid-abdominal incision for drug administration. The 
catheters were exteriorized through the interscapular skin. After 
2-day recovery period, the animals were placed for blood pressure 
recording in individual cylindrical cages containing food and water. 
The aortic catheter was connected to a blood pressure transducer 
via a rotating swivel that allowed the animals to move freely in the 
introduction
According  to  recent  reports  published  by  the  World  Health 
Organization, about 15 million people per year fall victim to stroke, 
one-third of whom die and another third are left permanently disa-
bled. Therefore, prevention is the only possible way to curb the stroke 
pandemic (Franco et al., 2004a,b; Papadopoulos and Papademetriou, 
2008). Hypertension is the most important modifiable risk for stroke. 
It is reported that over 70% of stroke can be attributed to hyper-
tension (Papadopoulos and Papademetriou, 2008). Blood pressure 
control is an important way to reduce the morbidity of stroke.
However, it is well accepted that blood pressure level is not the 
unique determinant for stroke in hypertension. Recently, we found 
that arterial baroreflex function, expressed as baroreflex sensitiv-
ity (BRS), is another important determinant for stroke (Liu et al., 
2007). Stroke-prone spontaneously hypertensive rats (SHR-SP) were 
divided into two groups according to their BRS at age of 6 months. 
It was found that stroke was significantly delayed in rats with high 
BRS compared with those with low BRS (Liu et al., 2007).
Based on these findings, we speculated that a combination of blood 
pressure reduction and BRS restoration might be much beneficial for 
preventing stroke in hypertension. The present work was therefore 
designed to test this hypothesis. Amlodipine was used for blood pres-
sure reduction and a small dose of ketanserin for BRS restoration. In 
this work, we used not only SHR-SP, but also a new spontaneous stroke 
model, two-kidney, two-clip (2K2C) renovascular hypertensive rats.Frontiers in Pharmacology  |  Cardiovascular and Smooth Muscle Pharmacology  July 2010  | Volume 1  | Article 6  |  2
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when drug A and drug B is used alone. (PA × PB) is the probability 
of rats responding to both drugs when they were used alone. When 
q < 0.85 the combination is antagonistic; when q > 1.15 it is syner-
gistic. It is additive when q is between 0.85 and 1.15.
protocol
Experiment 1
Effects of amlodipine, ketanserin and their combination on blood 
pressure and BRS in SHR-SP. In this experiment, 108 female SHR-SP 
aged 8 months were used. They were randomly divided into 12 groups 
(n = 9 in each group). After approximately 4-h habituation (from 8:00 
to 12:00), blood pressure was recorded during a period of 30 min (from 
12:00 to 12:30) and BRS was measured using the previously mentioned 
method. These values were taken as basal control values. After the deter-
mination of baseline values, each group of rats received intragastrically 
ketanserin (0.3, 1, 3 and 10 mg/kg), amlodipine (0.3, 1, 2, 3 mg/kg), 
or their combination (1 + 0.3, 1 + 1, 1 + 2, 1 + 3 mg/kg) respectively. 
Approximately 60 min after drug administration, blood pressure was 
recorded for another 30 min and BRS was determined again.
Experiment 2
Effects of amlodipine, ketanserin and their combination on stroke 
prevention in SHR-SP. Ninety male SHR-SP, aged 5 months, were 
randomly divided into six groups (n = 15 in each group). Drugs 
were mixed in the chow. The content of drugs in the rat chow was 
calculated according to consumption. The daily-ingested doses 
were as follows (shown in Table 1). The stroke occurrences, stroke 
subtypes and death time were recorded.
Experiment 3
Effects of amlodipine, ketanserin and their combination on stroke 
prevention in 2K2C rats. Total 120 male SD rats were randomly 
divided into six groups (n = 20 in each group). One month after 
2K2C operation, blood pressures were measured by tail-cuff plethys-
mography. Then these rats received treatments. The treatments were 
exactly the same as above-mentioned for SHR-SP (Table 1). Dead rats 
without stroke, but with obvious abnormity on other organs such as 
heart, lung, or kidney, were excluded from the protocol. The stroke 
occurrences, stroke subtypes and death time were recorded.
statistical analysis
Investigators were blind to the procedures during blood pressure 
and heart period recording, BRS determination, weighing and mor-
phological examination. Data are expressed as the mean ± SE. The 
comparisons between pre- and post-drug were made by paired t-tests. 
cage. After about 4-h habituation, the blood pressure signal was 
digitized by a microcomputer. SBP, DBP and heart period values 
were determined on line. The mean values of these parameters 
during a period of given time were calculated.
deterMination of Brs
In the above-mentioned blood pressure recording condition, BRS 
was measured in the conscious rat (Zhang et al., 2008). A bolus 
injection of phenylephrine was used to induce a blood pressure 
elevation. The dose of phenylephrine (5–10 μg/kg) was adjusted to 
raise SBP about 30 mmHg. There exists a delay (about 1 s) between 
the elevation of blood pressure (stimulus) and the prolongation of 
heart period (response) for arterial baroreflex. In rats, the heart rate 
is about 5 or 6 s. So, heart period was plotted against SBP for linear 
regression analysis for 2–8 shifts (calculated by computer); the slope 
with the largest correlation coefficient (r) of heart period/SBP was 
expressed as BRS (ms/mm Hg). The mean of two measurements 
with proper dose was taken as the final result.
preparation of 2K2c renovascular hypertensive rats
Male SD rats weighing 190–210 g were anesthetized with a combi-
nation of ketamine (40 mg/kg) and diazepam (6 mg/kg). A median 
longitudinal incision on abdominal skin was performed, and then 
two silver clips (0.3-mm internal gap) were placed on the roots of 
both right and left renal arteries (Zeng et al., 1998). All animals were 
fed standard rat chow and tap water ad libitum. One month after 
operation, SBP was measured by tail-cuff plethysmography.
stroKe syMptoM oBservation
To detect the stroke symptoms, the movement of limbs, respiration, 
diet, fur, and consciousness of all SHR-SP and 2K2C hypertensive 
rats were observed twice daily (at 8:00 and 18:00).
Morphological exaMination
In experiment 2 and 3, when the rats died, the brain was removed, 
and the signs of hemorrhage and ischemia were examined, and then 
photographed. Brains without these distinct signs were immersed 
in the solution of 4% paraformaldehyde in 0.1 mol/L phosphate 
buffer (pH 7.4), and then the brain was dissected and fixed in this 
solution for 24 h. The specimens were then washed, dehydrated 
in a graded ethanol series, and embedded in paraffin. Sections cut 
transversely at 5-μm thickness separated by 100 μm from the ante-
rior to the posterior extremity were stained with hematoxylin and 
eosin for light microscopic study (Xie et al., 2005).
proBaBility suM test
To determine whether the combination was synergistic, we used the 
probability sum test (q test) (Xie et al., 2005). This test came from 
classic probability analysis and was used for evaluating the synergism 
of the combination of two drugs. In the present work, we used the 
following criteria. Compared with the mean values of baseline (before 
drug administration), rats with a decrease of the mean value over 
4 h ≥ 20 mmHg in SBP were defined as responders. The formula is 
as follows: q = PA + B/(PA + PB−PA × PB). Here, A and B indicate drug 
A and drug B; P (probability) is the percentage of responders in each 
group. PA + B is real percentage of responder and (PA + PB−PA × PB) is 
expected response rate. (PA + PB) indicates the sum of the probabilities 
Table 1 | The doses of ketanserin and amlodipine in six groups.
Group  Dose (mg/kg/d)
  Ketanserin  Amlodipine
1  0  0
2  1  0
3  0  2
4  0.5  1
5  1  2
6  2  4www.frontiersin.org  July 2010  | Volume 1  | Article 6  |  3
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3.0 mg/kg, amlodipine significantly decreased SBP and DBP in a 
  dose-dependent manner. The maximal decrease (−22 mmHg) in 
SBP was found with 3 mg/kg. A significant decrease in heart period 
(increase in heart rate) existed with the doses from 1.0 mg/kg. A 
similar result was seen on BRS. Amlodipine enhanced BRS at the 
doses 1, 2, and 3 mg/kg. No effects on blood pressure were found 
when ketanserin was given at 0.3 mg/kg. From 1.0 mg/kg, ketanserin 
significantly decreased both SBP and DBP. It seems that the decrease 
in DBP was more profound than the decrease in SBP. Ketanserin did 
not affect heart period. The most important phenomenon is the effect 
In experiments 2 and 3, Kaplan-Meier analysis was used to estimate 
survival probabilities. Log-Rank testing was used to evaluate equality 
of survival curves. P < 0.05 was considered statistically significant.
results
effects of aMlodipine, Ketanserin and their coMBination on 
Blood pressure and Brs in shr-sp
The effects of a single dose of ketanserin and amlodipine, either 
alone  or  in  combination,  on  blood  pressure,  heart  period,  and 
BRS are shown in Figure 1. It was found that from 0.3 mg/kg to 
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FiGure 1 | The effects of a single dose of amlodipine (Aml) and ketanserin (Ket) or combination on systolic blood pressure (SBP), diastolic blood pressure 
(DBP), heart period (HP) and baroreflex sensitivity (BrS) in conscious SHr-SP . The values are expressed as mean ± SE. *P < 0.05, **P < 0.01 after drug vs. 
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Table 2 | The probability sum test in SHr-SP treated with ketanserin 
(Ket) and amlodipine (Aml) Alone or in combination.
Parameter  Dose (mg/kg)  P value (%)  q value
SBP
Ket   1  0 
Aml   0.3  0 
Aml   1  0 
Aml  2  33 
Aml  3  50 
Ket + Aml  1 + 0.3  29 
Ket + Aml  1 + 1  29 
Ket + Aml  1 + 2  80  2.4
Ket + Aml  1 + 3  89  1.8
DBP
Ket  1  10 
Aml  0.3  0 
Aml  1  43 
Aml  2  33 
Aml  3  50 
Ket + Aml  1 + 0.3  29 
Ket + Aml  1 + 1  57  1.17
Ket + Aml  1 + 2  70  2.1
Ket + Aml  1 + 3  100  1.8
BrS
Ket  1  60 
Aml  0.3  14 
Aml  1  14 
Aml  2  11 
Aml  3  50 
Ket + Aml  1 + 0.3  71  1.08
Ket + Aml  1 + 1  71  1.08
Ket + Aml  1 + 2  70  1.09
Ket + Aml  1 + 3  83  1.04
P indicated the percentage of animals possessing an effective decrease in BP 
(20 mm Hg), and an effective increase in BRS (0.2 ms/mm Hg) produced by 
ketanserin, amlodipine alone or in combination. n = 9 in each group.
of ketanserin on BRS. Even at very-low dose, ketanserin increased 
significantly BRS in SHR-SP. The effect of ketanserin on BRS was 
neither dose-dependent nor blood pressure dependent (Figure 1). In 
combination studies, the dose of ketanserin was fixed at 1.0 mg/kg. 
Ketanserin was combined with four different doses of amlodipine. 
It was found that the effects of the combinations on blood pressure 
were enhanced with the increase of the doses of amlodipine. However, 
this phenomenon was not found on BRS. The combination with the 
smallest dose of amlodipine had already a great effect.
The synergism of the combination was determined by q test. The 
q-test results are shown in Table 2. It is clear that there was a signifi-
cant synergism on blood pressure reduction for the combination of 
ketanserin and amlodipine. The best ratio of this combination was 
1:2. When 1 mg/kg ketanserin combined with 2 mg/kg amlodipine, 
we arrived at q values of 2.4 for SBP and 2.1 for DBP for the combi-
nation of ketanserin and amlodipine. But there was no synergistic 
interaction of ketanserin and amlodipine on BRS. The q values were 
all lower than 1.15 (1.04–1.09) and exhibited an additive effect.
effects of aMlodipine, Ketanserin and their coMBination on 
stroKe prevention in shr-sp
Among the 90 rats studied, 88 died from stroke were confirmed by 
displaying neurological symptoms of stroke and/or brain patho-
logical examination. About one-third animals died of hemor-
rhage and two-thirds of infarction. The subtypes of stroke are 
shown in Table 3. This proportion of hemorrhage and ischemia 
was not changed by the treatments. The survival time expressed 
by the Kaplan-Meier survival curve is shown in Figure 2. The 
average survival time in control SHR-SP was 332 ± 66 days. A sig-
nificant difference was detected between the control and the five 
drug treatment groups (Log-rank testing χ2 = 50.2, P < 0.0001). 
From Groups 2 to 6 (treated rats), the survival time was as fol-
lows: 398 ± 85 days; 404 ± 80 days; 424 ± 90 days; 470 ± 94 days; 
and 508 ± 93 days. Compared with control group, the survival 
time was 1.20-fold greater in Group 2 (P < 0.05), 1.22-fold in 
Group 3 (P < 0.05), 1.28-fold in Group 4 (P < 0.01), 1.42-fold 
in Group 5 (P < 0.001), and 1.53-fold in Group 6 (P < 0.001). 
When the control rats all died of stroke, the mortality rate in 
different treatment groups was as follows: 53% in Group 2; 
33% in Group 3; 27% in Group 4; 20% in Group 5; and 13% in 
Group 6. These data showed that the treatment can prevent the 
occurrence of stroke, especially the combination of amlodipine 
and ketanserin.
effects of aMlodipine, Ketanserin and their coMBination on 
stroKe prevention in 2K2c renovascular hypertensive rats
One month after 2K2C operation, blood pressures were meas-
ured  by  tail-cuff  plethysmography.  All  2K2C  rats  exhibited  a 
SBP > 150 mmHg. Among the 120 rats studied, 81 animals died 
from stroke. Other 39 animals died without stroke were excluded 
from the protocol. The subtypes of stroke are also shown in Table 3. 
This proportion of hemorrhage and ischemia was not changed by 
the treatments. The survival time expressed by the Kaplan-Meier 
survival curve is shown in Figure 3.
The average survival time in control rats was 194 ± 75 days. A 
significant difference was detected between the control and the five 
drug treatment groups (Log-rank testing χ2 = 31.2, P < 0.0001). 
From Groups 2 to 6 (treated rats), the survival time was as follows: 
277 ± 123 days; 310 ± 121 days; 354 ± 142 days; 364 ± 148 days; and 
381 ± 163 days. Compared with control group, the survival time 
was 1.43-fold greater in Group 2 (P < 0.05), 1.60-fold in Group 3 
(P < 0.01), 1.82-fold in Group 4 (P < 0.0001), 1.88-fold in Group 
5 (P < 0.0001), and 1.96-fold in Group 6 (P < 0.0001). When the 
control rats all died of stroke, the mortality rate in different treat-
ment groups was as follows: 67% in Group 2; 64% in Group 3; 
43% in Group 4; 36% in Group 5; and 38% in Group 6. These 
data also showed that the treatment can significantly prevent the 
occurrence of stroke, especially the combination of amlodipine 
and ketanserin.
discussion
It is estimated that over 70% of stroke can be attributed to hyperten-
sion. Blood pressure level is an important determinant for stroke. The 
risk of stroke is increased by about 25% with each 10 mmHg increase 
in SBP (Wolf-Maier et al., 2003; Fang et al., 2006; Luepker et al., 
2006). Accordingly, expected benefits of blood pressure   lowering www.frontiersin.org  July 2010  | Volume 1  | Article 6  |  5
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FiGure 2 | The effects of life-long treatment of ketanserin (Ket) and 
amlodipine (Aml) on the stroke death in SHr-SP . (A) The survival rate in these 
six subgroups (G, group), doses referred to Table 1, is expressed by Kaplan-Meier 
survival curves. (B) The survival time expressed as mean ± SE. *P < 0.05, 
**P < 0.01, ***P < 0.001 for treatment group vs control group. n = 14–15 in each 
group. (C) The mortality rate on day 404, when the control rats all died.
for stroke risk reduction are broadly consistent across a range of 
different population subgroups (Lawes et al., 2004; Papadopoulos 
and Papademetriou, 2008). In the present work, it was found that 
a  reduction  of  blood  pressure  with  amlodipine  (2  mg/kg/day) 
could significantly delay the occurrence of stroke and prolonged 
survival time in both SHR-SP (+72 days) and 2K2C hypertensive 
rats (+125 days).
Many researchers have confirmed that baroreflex   dysfunction 
was associated to the prognosis of many diseases (La Rovere et al., 
1988, 1998; Robinson et al., 2003). La Rovere and colleagues 
assessed BRS 4 weeks after the first attack of acute myocardial 
infarction. During a follow-up period of 2 years, they found that 
the mortality rate is 40% in patients with a BRS < 3.0 ms/mmHg 
while 3% in patients with a BRS > 3.0 ms/mmHg (La Rovere et al., 
Table 3 | Occurrence of brain lesions in different groups of SHr-SP and 2K2C rats.
Group  SHr-SP  2K2C
  n  Hem  isc  Mix  no Stroke  n  Hem  isc  Mix  no Stroke
1  15  4  8  3  0  20  4  7  4  5
2  15  5  6  4  0  20  3  7  5  5
3  15  4  9  2  0  20  3  8  3  6
4  15  4  8  3  0  20  2  7  5  6
5  15  3  8  3  1  20  4  7  3  6
6  15  4  6  4  1  20  3  6  4  7
Hem, hemorrhage; Isc, ischemia; Mix, mixture of Hem and Isc.Frontiers in Pharmacology  |  Cardiovascular and Smooth Muscle Pharmacology  July 2010  | Volume 1  | Article 6  |  6
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Based on above-mentioned data, the main working hypothesis 
of the present study is to propose that a combination of blood pres-
sure reduction and baroreflex restoration may be as a new strategy 
for stroke prevention in hypertension. To test this hypothesis, some 
considerations are listed as follows:
(1)  Drug selection. The antihypertensive effect of amlodipine 
is well recognized. In addition, it is believed as one of the 
best drugs for stroke prevention in hypertensive patients 
(Papadopoulos and Papademetriou, 2008). Since 20 years, 
we have studied many drugs for enhancing BRS. It was 
found that ketanserin is the most effective agent for barore-
flex restoration. Therefore, amlodipine and ketanserin were 
selected for blood pressure reduction and baroreflex resto-
ration respectively in this work.
(2)  Dose determination. The daily dose is 5–10 mg for amlodi-
pine and 40 mg for ketanserin clinically. We hope in clinic 
to use an ordinary dose of amlodipine and a small dose of 
ketanserin. Clinically, the daily dose for ketanserin is 4–8 
times greater than amlodipine. In the present work, ketan-
serin: amlodipine is 1:2. This means if we use an ordinary 
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FiGure 3 | The effects of life-long treatment of ketanserin and amlodipine 
on the stroke death in 2K2C rats. (A) The survival rate in these six subgroups 
(G, group), doses referred to Table 1, is expressed by Kaplan-Meier survival 
curves. (B) The survival time expressed as mean ± SE. *P < 0.05, **P < 0.01, 
***P < 0.001 for treatment group vs control group. n = 12–15 in each group. (C) 
The mortality rate on day 344, when the control rats all died.
1998). Robinson et al. (2003) reported that post-stroke patients 
with impaired BRS values had a significantly poorer prognosis 
than patients without impaired BRS. Recently, a series of studies 
concerning the baroreflex dysfunction and cardiovascular dis-
eases in rats was performed in our department. It was found that 
baroreflex dysfunction was related to: the severity of atheroscle-
rosis induced by high-cholesterol diet and the severity of acute 
cerebral ischemia induced by middle cerebral artery occlusion, 
the survival times in aconitine-induced ventricular arrhythmia, 
in endotoxin-induced shock and in SHR-SP (Cai et al., 2005; Liu 
et al., 2007, 2008).
Ketanserin is an antihypertensive drug with affinity for both 
5-HT2A and α1 receptors. Our previous studies demonstrated that 
ketanserin could effectively enhance BRS in SHR and SHR-SP (Fu 
et al., 2004). This effect is not blood pressure dependent as a small 
dose of ketanserin could enhance BRS without BP modification. 
In addition, this effect is mediated by central 5-HT2A receptor (Fu 
et al., 2004, 2006; Shen et al., 2007). Previously, we demonstrated 
that a small dose of ketanserin which did not decrease blood pres-
sure but enhanced BRS could effectively prolong the survival time 
in SHR-SP (Liu et al., 2007).www.frontiersin.org  July 2010  | Volume 1  | Article 6  |  7
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dose for amlodipine in clinic, that the dose of ketanserin is 
only 1/8 to 1/16 of the ordinary dose. It is a very small dose 
and this will be beneficial to patients requiring life-long 
treatment as the possible side effects will be minimized by 
such a small dose.
(3)  Animal models. SHR-SP is the best genetic animal model 
for studying the mechanism of the genesis of stroke and 
for testing the effectiveness of drugs in stroke prevention 
(Hamaguchi et al., 2008; Wang et al., 2008; Daneshtalab 
and Smeda, 2010; Henning et al., 2010). It is widely used 
and was certainly included in the present work. In addition, 
we used also another animal model, 2K2C   renovascular 
hypertensive rats. This non-genetic model was firstly esta-
blished by Zeng et al. (1998). The incidence of hyperten-
sion is 100% and the incidence of stroke is higher than 60% 
within 10 months after placing clips. Stroke subtypes in 
this animal model are similar to that in SHR-SP: about 1/3 
hemorrhage and 2/3 infarction.
The results showed that the combination of amlodipine and 
ketanserin could significantly prolonged survival time in both 
SHR-SP and 2K2C hypertensive rats. The effects of this com-
bination were significantly greater than those of mono-ther-
apies, even in the smallest dose group (1/2 dose of each drug 
used in mono-therapy). These results strongly confirmed our 
hypothesis.
In conclusion, combination of blood pressure reduction and 
baroreflex restoration possessed a superior preventive effect on 
stroke. It may be a new strategy for the prevention of stroke in 
hypertension.
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